Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure

Tasly Pharmaceuticals

Status and phase

Enrolling

Phase 1

Conditions

Heart Failure

Treatments

Drug: Jia Shen Tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT06348498

TSL-TCM-JSP-Ⅰb

Details and patient eligibility

About

Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in patients with Chronic Heart Failure.

Full description

Jia Shen Tablets are oral, compound traditional chinese medicine. This open label, standardise-loaded and single-Centre phase Ⅰb clinical trial will evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in treatment of coronary heart disease complicating chronic heart failure (syndrome of Yang deficiency with blood stasis) and preliminarily evaluate the efficacy and safety.

Enrollment

18 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18-75 years, either sex;
Meet the diagnostic criteria for CHD and CHF;
Meet the TCM differentiation criteria of yang deficiency and blood stasis in CHF;
LVEF < 40% (Modified Simpson's Method);
Class II to IⅢ for NYHA functional classification;
Receive Steady dose of standard medication for CHF for at least 2 weeks;
Understand the research requirements and are willing to provide written informed consent.

Exclusion criteria

Acute heart failure or acute exacerbation of chronic heart failure;
HF caused by other heart diseases, such as congenital heart disease, severe stenosis or insufficiency of heart valves, cardiomyopathy (e.g., hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy), moderate massive pericardial effusion, constrictive pericarditis, infective endocarditis;
Patients with acute coronary syndrome within 30 days before receiving the trial drug，and the following situation within 6 months before receiving the trial drug，such as acute myocardial infarction，revascularization (e.g., PCI, CABG) or left ventricular reconstruction surgery, pacemaker implantation for cardiac resynchronization, and undergoing cardiothoracic surgery;
Expect to receive an implantable device (e.g. ICD, CRT), or revascularization (e.g. PCI, CABG), or other cardiovascular surgery during the trial period;
Severe arrhythmias [e.g., ventricular tachycardia, second degree type II or higher sinus or atrioventricular block without pacemaker placement, QT interval (QTc) greater than 480 ms after heart rate adjustment according to Fridericia's formula, or known history or symptoms of long QT syndrome];
Combined with serious diseases of other systems, such as liver, kidney, hematopoietic system and other serious primary diseases, tumors, mental diseases, etc;
The presence of uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg), or the presence of hypotension (systolic blood pressure < 80 mmHg and/or diastolic blood pressure < 50 mmHg);
ALT or AST more than 3 times the upper limit of normal, and/or estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2;
Glycosylated hemoglobin (HbA1c) ≥9.0%, or fasting blood glucose ≥13.9 mmol/L;
Anemia (Hb < 110 g/L for women, Hb < 120 g/L for men);
Blood potassium is above the upper limit of normal;
Patients who tested positive for five hepatitis B tests (except surface antibodies) or hepatitis C, or anti-TP or HIV antibodies;
Patients with a history of drug abuse who test positive for drug abuse (morphine, methamphetamine, ketamine, dimethyldioxyamphetamine, THC, cocaine);
Women who are pregnant or nursing, or have a need to have children within 3 months after the last dose of the trial;
Participating in other studies and taking investigational drugs from other studies within 3 months prior to screening;
Allergic to Jiashen tablets or their ingredients;
Other situations judged by the researchers to be inappropriate for this study.